Zacks Research Has Strong Outlook for ALNY FY2024 Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Analysts at Zacks Research raised their FY2024 EPS estimates for Alnylam Pharmaceuticals in a research report issued on Wednesday, November 20th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings of ($2.52) per share for the year, up from their previous forecast of ($2.65). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.22) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($1.00) EPS, Q1 2025 earnings at ($0.95) EPS, Q2 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($3.26) EPS, Q1 2026 earnings at $0.33 EPS, Q2 2026 earnings at $0.09 EPS, Q3 2026 earnings at $0.64 EPS and FY2026 earnings at $1.71 EPS.

A number of other equities research analysts have also recently weighed in on the company. JPMorgan Chase & Co. upped their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. HC Wainwright restated a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Raymond James boosted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their target price for the company from $198.00 to $370.00 in a report on Friday, August 16th. Finally, Wolfe Research lowered shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $298.09.

Alnylam Pharmaceuticals Trading Down 0.8 %

Shares of ALNY opened at $244.89 on Monday. The firm’s 50-day moving average is $273.13 and its two-hundred day moving average is $238.67. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The firm has a market capitalization of $31.59 billion, a P/E ratio of -93.47 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. During the same period last year, the business posted $1.15 earnings per share. The company’s quarterly revenue was down 33.3% on a year-over-year basis.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently bought and sold shares of ALNY. Geode Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after purchasing an additional 66,928 shares during the period. TD Asset Management Inc grew its stake in Alnylam Pharmaceuticals by 6.0% during the second quarter. TD Asset Management Inc now owns 489,940 shares of the biopharmaceutical company’s stock worth $119,055,000 after buying an additional 27,592 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 3.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock worth $134,035,000 after acquiring an additional 16,756 shares in the last quarter. Avoro Capital Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 33.3% in the second quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Swiss National Bank raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the 3rd quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock valued at $103,246,000 after acquiring an additional 1,000 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.